Methylseleninic acid restricts tumor growth in nude mice model of metastatic breast cancer probably via inhibiting angiopoietin-2

BMC Cancer

Xiaojing Wu²  Yidi Zhang³  Zengyang Pei²  Si Chen²  Xu Yang²  Yin Chen¹  Degui Lin²  Runlin Z Ma³ 

[1] Department of Pathology, Beijing Sanbo Brain Hospital, Beijing, 100093, China

[2] The Clinical Department, College of Veterinary Medicine, China Agricultural University, Beijing, 100193, China

[3] The Graduate University of the Chinese Academy of Sciences, Beijing, 100149, China

关键词: Xenograft tumor;    MDA-MB-231 cells;    VEGF;    Ang-2;    MSeA;    Selenium;   

Others  :  1080415
DOI  :  10.1186/1471-2407-12-192

 received in 2012-01-19, accepted in 2012-05-28,  发布年份 2012

【 摘 要 】

Background

Angiopoietin-2 (Ang-2) plays critical roles in vascular morphogenesis and its upregulation is frequently associated with various tumors. Previous studies showed that certain selenium compounds possess anti-tumor effects. However, the underlining mechanism has not been elucidated in detail. Plus, results of research on the anti-tumor effects of selenium compounds remain controversial.

Methods

We investigated levels of Ang-2 and vascular endothelial growth factor (VEGF) on the estrogen-independent bone metastatic mammary cancer (MDA-MB-231) cells in response to treatment by methylseleninic acid (MSeA), and further examined the effects of MSeA oral administration on xenograft mammary tumors of athymic nude mice by RT-PCR, Western, radioimmuno assay, and Immunohistochemistry.

Results

Treatment of MDA-MB-231 cells with MSeA caused significant reduction of Ang-2 mRNA transcripts and secretion of Ang-2 proteins by the cells. Level of VEGF protein was accordingly decreased following the treatment. Compared with the controls, oral administration of MSeA (3 mg/kg/day for 18 days) to the nude mice carrying MDA-MB-231 induced tumors resulted in significant reduction in xenograft tumor volume and weights, significant decrease in microvascular density, and promotion of vascular normalization by increasing pericytes coverage. As expected, level of VEGF was also decreased in MSeA treated tumors.

Conclusions

Our results point out that MSeA exerts its anti-tumor effects, at least in part, by inhibiting the Ang-2/Tie2 pathway, probably via inhibiting VEGF.

【 授权许可】

   
2012 Wu et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]Almondes KG, Leal GV, Cozzolino SM, Philippi ST, Rondo PH: The role of selenoproteins in cancer. Rev Assoc Med Bras 2010, 56(4):484-488.
• [2]Kohrle J, Gartner R: Selenium and thyroid. Best Pract Res Clin Endocrinol Metabol 2009, 23(6):815-827.
• [3]Duntas LH: Selenium and the thyroid: a close-knit connection. J Clin Endocrinol Metab 2010, 95(12):5180-5188.
• [4]Burguera JL, Burguera M, Gallignani M, Alarcon OM, Burguera JA: Blood serum selenium in the province of Merida, Venezuela, related to sex, cancer incidence and soil selenium content. J Trace Elem Electrol Health Dis 1990, 4(2):73-77.
• [5]Knekt P, Marniemi J, Teppo L, Heliovaara M, Aromaa A: Is low selenium status a risk factor for lung cancer? Am J Epidemiol 1998, 148(10):975-982.
• [6]Russo MW, Murray SC, Wurzelmann JI, Woosley JT, Sandler RS: Plasma selenium levels and the risk of colorectal adenomas. Nutr Canc 1997, 28(2):125-129.
• [7]Young KJ, Lee PN: Intervention studies on cancer. Eur J Canc Prev 1999, 8(2):91-103.
• [8]Hu H, Jiang C, Li G, Lu J: PKB/AKT and ERK regulation of caspase-mediated apoptosis by methylseleninic acid in LNCaP prostate cancer cells. Carcinogenesis 2005, 26(8):1374-1381.
• [9]Jiang C, Wang Z, Ganther H, Lu J: Caspases as key executors of methyl selenium-induced apoptosis (anoikis) of DU-145 prostate cancer cells. Cancer Res 2001, 61(7):3062-3070.
• [10]Jiang C, Wang Z, Ganther H, Lu J: Distinct effects of methylseleninic acid versus selenite on apoptosis, cell cycle, and protein kinase pathways in DU145 human prostate cancer cells. Mol Cancer Ther 2002, 1(12):1059-1066.
• [11]Reagan-Shaw S, Nihal M, Ahsan H, Mukhtar H, Ahmad N: Combination of vitamin E and selenium causes an induction of apoptosis of human prostate cancer cells by enhancing Bax/Bcl-2 ratio. Prostate 2008, 68(15):1624-1634.
• [12]Wang Z, Jiang C, Lu J: Induction of caspase-mediated apoptosis and cell-cycle G1 arrest by selenium metabolite methylselenol. Mol Carcinog 2002, 34(3):113-120.
• [13]Jiang C, Ganther H, Lu J: Monomethyl selenium–specific inhibition of MMP-2 and VEGF expression: implications for angiogenic switch regulation. Mol Carcinog 2000, 29(4):236-250.
• [14]Jiang C, Jiang W, Ip C, Ganther H, Lu J: Selenium-induced inhibition of angiogenesis in mammary cancer at chemopreventive levels of intake. Mol Carcinog 1999, 26(4):213-225.
• [15]Wang Z, Hu H, Li G, Lee HJ, Jiang C, Kim SH, Lu J: Methylseleninic acid inhibits microvascular endothelial G1 cell cycle progression and decreases tumor microvessel density. Int J Cancer 2008, 122(1):15-24.
• [16]Wang Z, Jiang C, Ganther H, Lu J: Antimitogenic and proapoptotic activities of methylseleninic acid in vascular endothelial cells and associated effects on PI3K-AKT, ERK, JNK and p38 MAPK signaling. Cancer Res 2001, 61(19):7171-7178.
• [17]Sinha I, Null K, Wolter W, Suckow MA, King T, Pinto JT, Sinha R: Methylseleninic acid downregulates hypoxia-inducible factor-1alpha in invasive prostate cancer. Int J Cancer 2011, 130(6):1430-1439.
• [18]Bhattacharya A: Methylselenocysteine: a promising antiangiogenic agent for overcoming drug delivery barriers in solid malignancies for therapeutic synergy with anticancer drugs. Expet Opin Drug Deliv 2011, 8(6):749-763.
• [19]Bhattacharya A, Seshadri M, Oven SD, Toth K, Vaughan MM, Rustum YM: Tumor vascular maturation and improved drug delivery induced by methylselenocysteine leads to therapeutic synergy with anticancer drugs. Clin Cancer Res 2008, 14(12):3926-3932.
• [20]Bhattacharya A, Toth K, Sen A, Seshadri M, Cao S, Durrani FA, Faber E, Repasky EA, Rustum YM: Inhibition of colon cancer growth by methylselenocysteine-induced angiogenic chemomodulation is influenced by histologic characteristics of the tumor. Clin Colorectal Cancer 2009, 8(3):155-162.
• [21]Zhang J, Wang L, Li G, Anderson LB, Xu Y, Witthuhn B, Lu J: Mouse prostate proteomes are differentially altered by supranutritional intake of four selenium compounds. Nutr Canc 2011, 63(5):778-789.
• [22]Chemoprevention Database In. http://www.inra.fr/reseau-nacre/sci-memb/corpet/indexan.html webcite
• [23]Clark LC, Combs GF, Turnbull BW, Slate EH, Chalker DK, Chow J, Davis LS, Glover RA, Graham GF, Gross EG, et al.: Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 1996, 276(24):1957-1963.
• [24]Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, et al.: Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009, 301(1):39-51.
• [25]Wang L, Bonorden MJ, Li GX, Lee HJ, Hu H, Zhang Y, Liao JD, Cleary MP, Lu J: Methyl-selenium compounds inhibit prostate carcinogenesis in the transgenic adenocarcinoma of mouse prostate model with survival benefit. Canc Prev Res Phila 2009, 2(5):484-495.
• [26]Mazzieri R, Pucci F, Moi D, Zonari E, Ranghetti A, Berti A, Politi LS, Gentner B, Brown JL, Naldini L, et al.: Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Canc Cell 2011, 19(4):512-526.
• [27]Roskoski R: Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit Rev Oncol Hematol 2007, 62(3):179-213.
• [28]Saharinen P, Eklund L, Pulkki K, Bono P, Alitalo K: VEGF and angiopoietin signaling in tumor angiogenesis and metastasis. Trends Mol Med 2011, 17(7):347-362.
• [29]Cao S, Durrani FA, Rustum YM: Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts. Clin Cancer Res 2004, 10(7):2561-2569.
• [30]Koga K, Todaka T, Morioka M, Hamada J, Kai Y, Yano S, Okamura A, Takakura N, Suda T, Ushio Y: Expression of angiopoietin-2 in human glioma cells and its role for angiogenesis. Cancer Res 2001, 61(16):6248-6254.
• [31]Hashizume H, Falcon BL, Kuroda T, Baluk P, Coxon A, Yu D, Bready JV, Oliner JD, McDonald DM: Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res 2010, 70(6):2213-2223.
• [32]Zhang L, Yang N, Park JW, Katsaros D, Fracchioli S, Cao G, O'Brien-Jenkins A, Randall TC, Rubin SC, Coukos G: Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. Cancer Res 2003, 63(12):3403-3412.
• [33]Loughna S, Sato TN: Angiopoietin and Tie signaling pathways in vascular development. Matrix Biol 2001, 20(5–6):319-325.
• [34]Thomas M, Augustin HG: The role of the Angiopoietins in vascular morphogenesis. Angiogenesis 2009, 12(2):125-137.
• [35]Zadeh G, Koushan K, Baoping Q, Shannon P, Guha A: Role of angiopoietin-2 in regulating growth and vascularity of astrocytomas. J Oncol 2010, 2010:659231.
• [36]Brown JL, Cao ZA, Pinzon-Ortiz M, Kendrew J, Reimer C, Wen S, Zhou JQ, Tabrizi M, Emery S, McDermott B, et al.: A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models. Mol Cancer Ther 2010, 9(1):145-156.
• [37]Falcon BL, Hashizume H, Koumoutsakos P, Chou J, Bready JV, Coxon A, Oliner JD, McDonald DM: Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels. Am J Pathol 2009, 175(5):2159-2170.
• [38]Feng Y, vom Hagen F, Pfister F, Djokic S, Hoffmann S, Back W, Wagner P, Lin J, Deutsch U, Hammes HP: Impaired pericyte recruitment and abnormal retinal angiogenesis as a result of angiopoietin-2 overexpression. Thromb Haemost 2007, 97(1):99-108.
• [39]Bos R, van Diest PJ, de Jong JS, van der Groep P, van der Valk P, van der Wall E: Hypoxia-inducible factor-1alpha is associated with angiogenesis, and expression of bFGF, PDGF-BB, and EGFR in invasive breast cancer. Histopathology 2005, 46(1):31-36.
• [40]Vermeulen PB, Gasparini G, Fox SB, Colpaert C, Marson LP, Gion M, Belien JA, de Waal RM, Van Marck E, Magnani E, et al.: Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer 2002, 38(12):1564-1579.
• [41]Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, Augustin HG: Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 2000, 60(5):1388-1393.
• [42]Simms D, Cizidziel PE, Chomczynski P: TRIZOL™: A new reagent for optimal single-step isolation of RNA. Focus 1994, 15(4):99-102.
• [43]Acebedo G, Hayek A, Klegerman M, Crolla L, Bermes E, Brooks M: A rapid ultramicro radioimmunoassay for human thyrotropin. Biochem Biophys Res Commun 1975, 65(2):449-456.